Washington Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Washington Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,400	Closed	-$624K	–	121
2025 Q4	$624K	Sell	4,400 -800	-15%	-$116K	0.51%	58
2025 Q3	$730K	Sell	5,200 -1,000	-16%	-$135K	0.52%	43
2025 Q2	$779K	Buy	6,200 +1,800	+41%	+$206K	0.58%	39
2025 Q1	$487K	Sell	4,400 -700	-14%	-$88.7K	0.39%	77
2024 Q4	$696K	Hold	5,100	–	–	0.55%	40
2024 Q3	$588K	Buy	5,100 +1,800	+55%	+$247K	0.45%	65
2024 Q2	$454K	Sell	3,300 -700	-18%	-$96K	0.38%	79
2024 Q1	$552K	Sell	4,000 -750	-16%	-$102K	0.45%	76
2023 Q4	$626K	Sell	4,750 -1,000	-17%	-$115K	0.54%	55
2023 Q3	$647K	Hold	5,750	–	–	0.59%	46
2023 Q2	$542K	Buy	5,750 +750	+15%	+$73.3K	0.46%	66
2023 Q1	$506K	Hold	5,000	–	–	0.45%	73
2022 Q4	$597K	Sell	5,000 -1,500	-23%	-$176K	0.55%	50
2022 Q3	$690K	Hold	6,500	–	–	0.7%	39
2022 Q2	$634K	Hold	6,500	–	–	0.61%	45
2022 Q1	$609K	Hold	6,500	–	–	0.5%	56
2021 Q4	$554K	Hold	6,500	–	–	0.45%	75
2021 Q3	$623K	Hold	6,500	–	–	0.55%	46
2021 Q2	$633K	Hold	6,500	–	–	0.77%	42
2021 Q1	$632K	Hold	6,500	–	–	0.59%	51
2020 Q4	$623K	Buy	6,500 +1,100	+20%	+$106K	0.59%	50
2020 Q3	$519K	Buy	+5,400	New	+$625K	0.53%	67

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Washington Capital Management's NBIX Position: Q1 2026 in Review

Washington Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 4,400 shares — an estimated $624K sold.

Washington Capital Management first reported a position in NBIX in Q3 2020 and held it in 22 quarters. The position peaked at $779K in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Washington Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Washington Capital Management sold 4,400 Neurocrine Biosciences shares in Q1 2026, an estimated $624K.
Washington Capital Management first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 22 quarters.
Washington Capital Management's Neurocrine Biosciences position peaked at $779K in Q2 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Washington Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.